Keenova Therapeutics plc 8-K

What Happened Keenova Therapeutics plc announced on July 8, 2026 (Form 8-K) that its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum) for plantar fibromatosis (PFI) met its primary endpoint, showing a statistically significant and clinically meaningful improvement in pain versus placebo as measured by Average Daily Pain Intensity on the Numeric Rating Scale. The company also reported that key ranked secondary endpoints—difficulty and activity limitation on the Foot Function Index (FFI)—were met, and additional secondary measures showed statistically significant improvements.

Key Details

• Filing: Current Report on Form 8-K dated July 8, 2026; press release furnished as Exhibit 99.1.
• Primary endpoint: Statistically significant improvement in Average Daily Pain Intensity (Numeric Rating Scale) versus placebo.
• Secondary endpoints: Met key ranked FFI measures (difficulty and activity limitation); additional significant improvements in FFI pain subscale, global assessments, treatment satisfaction, and nodule characteristics.
• Safety: Safety profile consistent with known XIAFLEX data from approved indications; most adverse events were mild to moderate and there were no treatment-related serious adverse events.

Why It Matters For investors, the Phase 3 success is a major clinical milestone that supports potential regulatory advancement of XIAFLEX for plantar fibromatosis, a chronic condition with limited medical treatment options. Positive efficacy across pain and functional measures, together with a consistent safety profile, could affect future regulatory filings, labeling, market opportunity, and commercial planning for Keenova — though the company has not announced regulatory submissions or commercial timelines in this filing.